PMID- 35634570
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2040-6223 (Print)
IS  - 2040-6231 (Electronic)
IS  - 2040-6223 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and safety of intravenous immunoglobulin for treating refractory 
      livedoid vasculopathy: a systematic review.
PG  - 20406223221097331
LID - 10.1177/20406223221097331 [doi]
LID - 20406223221097331
AB  - INTRODUCTION: Intravenous immunoglobulin (IVIG) was reported to be the third most 
      used monotherapy in livedoid vasculopathy (LV). There is currently a lack of 
      randomized controlled clinical trials and no standardized therapeutic regimen for 
      IVIG therapy in LV. METHODS: We performed a systematic review of the efficacy and 
      safety of IVIG in treating patients with LV using PubMed, Cochrane, and Embase 
      databases. RESULTS: Eighty LV patients from 17 articles were included, receiving 
      IVIG therapy at a dose of 1-2.1 g/kg body weight every 4 weeks. The effective 
      rate of IVIG therapy in LV patients was 95% (76/80) in published studies, showing 
      a good clinical response for resolution of pain, skin ulcerations, and 
      neurological symptoms, and reducing the dependence on glucocorticoids and 
      immunosuppressive agents. IVIG therapy was well tolerated, and no severe adverse 
      events were observed. CONCLUSION: Overall, to a certain degree, IVIG is probably 
      a safe and effective treatment alternative for refractory LV patients, which 
      still need to be confirmed by large-scale randomized controlled clinical trials.
CI  - (c) The Author(s), 2022.
FAU - Gao, Yimeng
AU  - Gao Y
AUID- ORCID: 0000-0002-3717-224X
AD  - Department of Dermatology, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Science and Peking Union Medical College, National Clinical Research Center for 
      Dermatologic and Immunologic Diseases, Beijing, China.
FAU - Jin, Hongzhong
AU  - Jin H
AD  - Department of Dermatology, State Key Laboratory of Complex Severe and Rare 
      Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 
      Science and Peking Union Medical College, National Clinical Research Center for 
      Dermatologic and Immunologic Diseases, No.1 Shuaifuyuan, Dongcheng district, 
      Beijing, 100730 China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220522
PL  - United States
TA  - Ther Adv Chronic Dis
JT  - Therapeutic advances in chronic disease
JID - 101532140
PMC - PMC9134453
OTO - NOTNLM
OT  - intravenous immunoglobulin
OT  - livedoid vasculopathy
OT  - treatment
OT  - vascular disease
COIS- Conflict of interest statement: The authors declared no potential conflicts of 
      interest with respect to the research, authorship, and/or publication of this 
      article.
EDAT- 2022/06/01 06:00
MHDA- 2022/06/01 06:01
PMCR- 2022/05/22
CRDT- 2022/05/31 09:57
PHST- 2021/11/08 00:00 [received]
PHST- 2022/04/12 00:00 [accepted]
PHST- 2022/05/31 09:57 [entrez]
PHST- 2022/06/01 06:00 [pubmed]
PHST- 2022/06/01 06:01 [medline]
PHST- 2022/05/22 00:00 [pmc-release]
AID - 10.1177_20406223221097331 [pii]
AID - 10.1177/20406223221097331 [doi]
PST - epublish
SO  - Ther Adv Chronic Dis. 2022 May 22;13:20406223221097331. doi: 
      10.1177/20406223221097331. eCollection 2022.